General Psychopharmacology and Emerging Treatments is organized by Pri-Med.
Release Date: 8/28/2025
Expiration Date: 12/22/2026
Description:
The study of the treatment of psychiatric illness is constantly evolving, and several new medications have been recently approved for diagnoses such as mood disorders and schizophrenia. Many of these new medications have novel mechanisms of action, and thus they are a significant departure from older medications. This session will review the latest developments in psychopharmacology with which all primary care clinicians should be familiar.
Learning Objectives:
Topics:
Accreditation Statement
Pri-Med Institute is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation Statement:
Pri-Med Institute designates this enduring material for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
AANP
Accreditation Statement:
Pri-Med Institute is accredited by the American Association of Nurse Practitioners® as an approved provider of nurse practitioner continuing education.
Designation Statement:
This activity is approved for 1.00 contact hour of continuing education, which includes 1.00 hours of pharmacology.
MOC Credit Information:
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.00 Medical Knowledge MOC point in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Copyrights © 2026 eMedEvents Corporation, All Rights Reserved